Bell’s palsy: facial-nerve weakness, urgent alternatives, eye protection, early treatment, recovery, and antiviral uncertainty

Different words refer to different problems

A new facial droop should not automatically be treated as Bell’s palsy

The NHS identifies facial droop with arm weakness or speech difficulty as possible stroke symptoms requiring emergency help. Suspected Bell’s palsy also needs prompt assessment. This distinction is not a home forehead-movement test that reliably excludes an emergency.[1]

The presumed mechanism does not identify a virus in every person

MedlinePlus describes facial-nerve inflammation, with a cause that is often unclear. Herpes viruses may be involved, while Lyme disease and other disorders can produce similar weakness. A plausible viral mechanism does not by itself establish the benefit of a particular antiviral regimen.[2]

Movement, taste, sound and eye comfort can all change

The NHS describes drooling, loss of taste, a dry or watering eye and difficulty closing the affected eyelid. Symptoms usually develop over a few days. A watery eye does not establish that its surface is adequately protected, and appearance alone does not measure every functional consequence.[1]

Tests investigate selected alternatives

MedlinePlus describes history and examination, with selected blood, electrical nerve or imaging tests when another cause is suspected. Not every person needs an identical investigation. An EMG assesses nerve–muscle function; an MRI investigates a different structural question. Neither replaces the assessment of a new presentation.[2]

Incomplete eyelid closure needs specific protection

MedlinePlus describes lubricating drops or ointment and selected nighttime protection, because a drying cornea can develop injury and vision problems. The appropriate method requires clinical instruction. Improvement in the smile and protection of the eye are different care goals.[2]

Early assessment matters for treatment opportunities

The NHS explains that treatment works better when started early, within seventy-two hours. This concerns clinician-assessed treatment after onset, rather than permission to self-start leftover steroids or wait until the end of that window.[1]

Adding an antiviral has different evidence for different endpoints

The 2019 Cochrane update searched through July 2019. In its lower-bias analysis of three trials and 766 participants, adding antivirals to corticosteroids gave an incomplete-recovery risk ratio of 0.81, 95% confidence interval 0.38–1.74. The wide interval and low published certainty did not establish a clear recovery advantage.[4]

A separate analysis suggested fewer long-term synkinesis or tearing effects, while adverse-event evidence was very uncertain. These findings can coexist because the outcomes differ. The review does not establish a universal antiviral requirement, zero drug risk or a complete current pediatric treatment rule.[4]

Most improve, but continuing difficulties deserve follow-up

The NHS describes recovery commonly over months, with longer-lasting weakness or practical and emotional effects in some people. It recommends reassessment if improvement has not begun after several weeks. A population expectation should not become a promise or a reason to dismiss difficulty eating, speaking or coping.[1]

Published questions

The 2016 review found fewer incomplete recoveries

The Cochrane review searched through March 2016 and pooled seven trials with 895 evaluable participants. At six months or later, incomplete facial recovery occurred in 17% receiving corticosteroids and 28% in controls: risk ratio 0.63, 95% confidence interval 0.50–0.80. The estimated number needed to treat was ten, with an interval of six to twenty.[3]

That estimate describes the studied populations and comparisons. It is not a personal prediction, and a similar rate of reported adverse effects does not establish universal safety in every comorbidity. The review reported differing confidence for facial recovery and cosmetic sequelae. Full trial-level eligibility and harms were not appraised here.[3]

The 2007 trial evaluated treatment factors, not just two named groups

Sullivan and colleagues randomized 551 people within seventy-two hours; final outcomes were assessed in 496. The factorial design compared prednisolone and acyclovir separately and together. At three months, facial recovery was 83.0% with prednisolone versus 63.6% without it; at nine months, 94.4% versus 81.6%. These factor comparisons pooled the relevant treatment arms.[5]

The trial did not show an acyclovir recovery benefit. It was commissioned through the UK Health Technology Assessment program. Complete protocol and contemporary comparisons were not appraised. Its findings and later pooled reviews may share evidence; a trial and a review are not automatically independent replication.[5]

A second large trial distinguishes steroids from antivirals

The 2008 Scandinavian trial analyzed 829 adults presenting within 72 hours and followed facial recovery for 12 months. Prednisolone shortened time to complete recovery; valaciclovir did not. This adds a separate large comparison to the earlier trial. It supports the steroid–antiviral distinction while retaining the early-presentation population; it does not establish the same effect when treatment begins much later or when facial weakness has another cause.[6]

References

1. Bell’s palsy

   Agency condition or prevention explanation

   NHS · Content/publication date: 2023
   Accessed: 2026-10-09 UTC · Selected relevant original official page passages inspected
   Cited sections: July 2023: urgent alternatives, early assessment, symptoms and recovery

2. Bell palsy: Medical Encyclopedia

   Agency condition or prevention explanation

   A.D.A.M. clinical editors / MedlinePlus · Content/publication date: 2026
   Accessed: 2026-10-09 UTC · Original indexed clinically reviewed encyclopedia passages inspected
   Cited sections: May 2026: facial nerve, uncertain cause, selected assessment and corneal protection

3. Corticosteroids for Bell’s palsy

   Systematic review

   Madhok VB, Gagyor I and colleagues / Cochrane · Content/publication date: 2016
   Accessed: 2026-10-09 UTC · Original indexed review summary and selected methods/results inspected; no independent full-text appraisal
   Cited sections: July 2016: March search, incomplete recovery, NNT/precision and differing sequelae evidence

   Original review summary/abstract inspected; full eligibility/harms appraisal incomplete.

4. Antiviral treatment for Bell’s palsy

   Systematic review

   Gagyor I, Madhok VB, Daly F, Sullivan F / Cochrane · Content/publication date: 2019
   Accessed: 2026-10-09 UTC · Original indexed review summary and selected methods/results inspected; no independent full-text appraisal
   Cited sections: September 2019: July search, lower-bias analyses, endpoint differences and uncertain harms

   Recovery and long-term sequelae are separate endpoints; newer full comparisons pending.

5. Early Treatment with Prednisolone or Acyclovir in Bell’s Palsy

   Randomized trial

   Sullivan FM, Swan IRC and colleagues · Content/publication date: 2007
   Accessed: 2026-10-09 UTC · Original indexed abstract and selected original introduction inspected; complete protocol/harms appraisal incomplete
   Cited sections: 2007: factorial design, early treatment, attrition, recovery and HTA commissioning

   Trial and subsequent reviews may overlap; full study-list reconciliation pending.

6. Prednisolone and valaciclovir in Bell’s palsy

   Randomized trial

   Engström M and colleagues · Content/publication date: not stated
   Accessed: 2026-10-13 UTC · Original relevant abstract or source text retrieved and inspected
   Cited sections: 2008 abstract: 829 analyzed, within 72 hours, 12 months, Sunnybrook recovery and antiviral comparison

   Added targeted evidence or explanation; no exhaustive current appraisal.

Scope & review

Population

Readers exploring clinician-assessed idiopathic facial palsy; other causes and pediatric applicability differ

Exposure or intervention

Facial-nerve function, urgent alternatives, eye protection, early steroids, antiviral endpoints and recovery

Comparison

Source-specific symptom, care, screening or comparator settings

Outcomes

Facial recovery, corneal protection, synkinesis, tearing, daily function and treatment harms

Timeframe

Early hours-to-days assessment; six-to-nine-month selected outcomes and variable later recovery

Jurisdiction

Selected US/UK agency and professional guidance; jurisdiction and eligibility differences are labeled

Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.

Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.

What this article still leaves open

• Current pediatric trials, facial rehabilitation and complete review/trial overlap need fuller appraisal.
• Persistent synkinesis, alternative facial-nerve diagnoses, prognostic testing and procedure comparisons need dedicated coverage.
• Qualified review, personal facial-weakness diagnosis, medicine selection and eye-treatment instructions are not supplied.

Related reading

Explore the topic map

Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.